In this context, monalizumab, a mAb that blocks NKG2A-HLA-E interaction, shows potent anti-tumor activity and may significantly enhance the NK cell-mediated graft vs. leukemia (GvL) effect [33,156]. Here, HLA-E is linked to neoplasm.